Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 95

1.

Status of implementation and organization of cancer screening in The European Union Member States-Summary results from the second European screening report.

Basu P, Ponti A, Anttila A, Ronco G, Senore C, Vale DB, Segnan N, Tomatis M, Soerjomataram I, Primic Žakelj M, Dillner J, Elfström KM, Lönnberg S, Sankaranarayanan R.

Int J Cancer. 2017 Sep 23. doi: 10.1002/ijc.31043. [Epub ahead of print]

PMID:
28940326
2.

Time trends and spatial patterns in the mesothelioma incidence in Slovenia, 1961-2014.

Zadnik V, Primic Zakelj M, Jarm K, Zagar T.

Eur J Cancer Prev. 2017 Sep;26 Joining forces for better cancer registration in Europe:S191-S196. doi: 10.1097/CEJ.0000000000000384.

PMID:
28914691
3.

Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: A EUROCARE-5 study.

Minicozzi P, Innos K, Sánchez MJ, Trama A, Walsh PM, Marcos-Gragera R, Dimitrova N, Botta L, Visser O, Rossi S, Tavilla A, Sant M; EUROCARE-5 Working Group.

Eur J Cancer. 2017 Oct;84:335-353. doi: 10.1016/j.ejca.2017.07.015. Epub 2017 Sep 1.

PMID:
28865261
4.

Breast cancer in South-Eastern European countries since 2000: Rising incidence and decreasing mortality at young and middle ages.

Dimitrova N, Znaor A, Agius D, Eser S, Sekerija M, Ryzhov A, Primic-Žakelj M, Coebergh JW; SEE+ Working Group.

Eur J Cancer. 2017 Sep;83:43-55. doi: 10.1016/j.ejca.2017.06.011. Epub 2017 Jul 14.

PMID:
28711578
5.

Geographical variability in survival of European children with central nervous system tumours.

Gatta G, Peris-Bonet R, Visser O, Stiller C, Marcos-Gragera R, Sánchez MJ, Lacour B, Kaatsch P, Berrino F, Rutkowski S, Botta L; EUROCARE-5 Working Group.

Eur J Cancer. 2017 Sep;82:137-148. doi: 10.1016/j.ejca.2017.05.028. Epub 2017 Jul 6.

PMID:
28689091
6.

Erratum to "Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)" [Gynecol. Oncol. 144 (2017) 396-404].

Matz M, Coleman MP, Carreira H, Salmerón D, Chirlaque MD, Allemani C; CONCORD Working Group.

Gynecol Oncol. 2017 Jul 5. pii: S0090-8258(17)30974-5. doi: 10.1016/j.ygyno.2017.06.033. [Epub ahead of print] No abstract available.

PMID:
28688523
7.

Erratum to "The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2)" [Gynecol. Oncol. 144 (2017) 405-413].

Matz M, Coleman MP, Sant M, Chirlaque MD, Visser O, Gore M, Allemani C; CONCORD Working Group; Africa.

Gynecol Oncol. 2017 Jul 5. pii: S0090-8258(17)30973-3. doi: 10.1016/j.ygyno.2017.06.032. [Epub ahead of print] No abstract available.

PMID:
28687170
8.

Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries.

Bonaventure A, Harewood R, Stiller CA, Gatta G, Clavel J, Stefan DC, Carreira H, Spika D, Marcos-Gragera R, Peris-Bonet R, Piñeros M, Sant M, Kuehni CE, Murphy MFG, Coleman MP, Allemani C; CONCORD Working Group.

Lancet Haematol. 2017 May;4(5):e202-e217. doi: 10.1016/S2352-3026(17)30052-2. Epub 2017 Apr 11.

9.

International incidence of childhood cancer, 2001-10: a population-based registry study.

Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, Hesseling P, Shin HY, Stiller CA; IICC-3 contributors.

Lancet Oncol. 2017 Jun;18(6):719-731. doi: 10.1016/S1470-2045(17)30186-9. Epub 2017 Apr 11.

10.

Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5.

Dal Maso L, Tavilla A, Pacini F, Serraino D, van Dijk BAC, Chirlaque MD, Capocaccia R, Larrañaga N, Colonna M, Agius D, Ardanaz E, Rubió-Casadevall J, Kowalska A, Virdone S, Mallone S, Amash H, De Angelis R; EUROCARE-5 Working Group.

Eur J Cancer. 2017 May;77:140-152. doi: 10.1016/j.ejca.2017.02.023. Epub 2017 Apr 11.

PMID:
28410490
11.

Cancer burden in slovenia with the time trends analysis.

Zadnik V, Primic Zakelj M, Lokar K, Jarm K, Ivanus U, Zagar T.

Radiol Oncol. 2017 Feb 22;51(1):47-55. doi: 10.1515/raon-2017-0008. eCollection 2017 Mar 1.

12.

The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2).

Matz M, Coleman MP, Sant M, Chirlaque MD, Visser O, Gore M, Allemani C; & the CONCORD Working Group.

Gynecol Oncol. 2017 Feb;144(2):405-413. doi: 10.1016/j.ygyno.2016.10.019. Epub 2016 Dec 6.

PMID:
27931752
13.

Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2).

Matz M, Coleman MP, Carreira H, Salmerón D, Chirlaque MD, Allemani C; CONCORD Working Group.

Gynecol Oncol. 2017 Feb;144(2):396-404. doi: 10.1016/j.ygyno.2016.11.019. Epub 2016 Dec 2.

PMID:
27919574
14.

Common variables in European pancreatic cancer registries: The introduction of the EURECCA pancreatic cancer project.

de Leede EM, Sibinga Mulder BG, Bastiaannet E, Poston GJ, Sahora K, Van Eycken E, Valerianova Z, Mortensen MB, Dralle H, Primic-Žakelj M, Borràs JM, Gasslander T, Ryzhov A, Lemmens VE, Mieog JS, Boelens PG, van de Velde CJ, Bonsing BA.

Eur J Surg Oncol. 2016 Sep;42(9):1414-9. doi: 10.1016/j.ejso.2016.03.011. Epub 2016 Mar 28.

PMID:
27061790
15.

Disparities in melanoma incidence and mortality in South-Eastern Europe: Increasing incidence and divergent mortality patterns. Is progress around the corner?

Barbaric J, Sekerija M, Agius D, Coza D, Dimitrova N, Demetriou A, Safaei Diba C, Eser S, Gavric Z, Primic-Zakelj M, Zivkovic S, Zvolsky M, Bray F, Coebergh JW, Znaor A.

Eur J Cancer. 2016 Mar;55:47-55. doi: 10.1016/j.ejca.2015.11.019. Epub 2016 Jan 9.

PMID:
26773419
16.

Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diffuse large B-cell lymphoma: comparison between European population-based data (EUROCARE-5).

Mounier M, Bossard N, Remontet L, Belot A, Minicozzi P, De Angelis R, Capocaccia R, Iwaz J, Monnereau A, Troussard X, Sant M, Maynadié M, Giorgi R; EUROCARE-5 Working Group; CENSUR Working Survival Group.

Lancet Haematol. 2015 Nov;2(11):e481-91. doi: 10.1016/S2352-3026(15)00155-6. Epub 2015 Oct 23.

PMID:
26686258
17.

Cancer survival in Europe, 1999-2007: Doing better, feeling worse?

Sant M, Minicozzi P, Primic-Žakelj M, Otter R, Francisci S, Gatta G, Berrino F, De Angelis R.

Eur J Cancer. 2015 Oct;51(15):2101-2103. doi: 10.1016/j.ejca.2015.08.019. Epub 2015 Sep 26. No abstract available.

PMID:
26421814
18.

European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk.

Schüz J, Espina C, Villain P, Herrero R, Leon ME, Minozzi S, Romieu I, Segnan N, Wardle J, Wiseman M, Belardelli F, Bettcher D, Cavalli F, Galea G, Lenoir G, Martin-Moreno JM, Nicula FA, Olsen JH, Patnick J, Primic-Zakelj M, Puska P, van Leeuwen FE, Wiestler O, Zatonski W; Working Groups of Scientific Experts.

Cancer Epidemiol. 2015 Dec;39 Suppl 1:S1-10. doi: 10.1016/j.canep.2015.05.009. Epub 2015 Jul 9.

19.

The impact of cancer incidence and stage on optimal utilization of radiotherapy: Methodology of a population based analysis by the ESTRO-HERO project.

Borras JM, Barton M, Grau C, Corral J, Verhoeven R, Lemmens V, van Eycken L, Henau K, Primic-Zakelj M, Strojan P, Trojanowski M, Dyzmann-Sroka A, Kubiak A, Gasparotto C, Defourny N, Malicki J, Dunscombe P, Coffey M, Lievens Y.

Radiother Oncol. 2015 Jul;116(1):45-50. doi: 10.1016/j.radonc.2015.04.021. Epub 2015 May 19.

PMID:
26002304
20.

The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis.

Borras JM, Lievens Y, Dunscombe P, Coffey M, Malicki J, Corral J, Gasparotto C, Defourny N, Barton M, Verhoeven R, van Eycken L, Primic-Zakelj M, Trojanowski M, Strojan P, Grau C.

Radiother Oncol. 2015 Jul;116(1):38-44. doi: 10.1016/j.radonc.2015.04.018. Epub 2015 May 14.

PMID:
25981052

Supplemental Content

Loading ...
Support Center